English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

BACKGROUND  Central venous catheter (CVC) occlusion is common, affecting 30% of all CVCs.    OBJECTIVE  To compare length of stay (LOS), costs, and readmissions associated with the use of alteplase to clear catheter blockage to outcomes associated with catheter replacement.    DESIGN  Retrospective observational study utilizing a large hospital database.    PARTICIPANTS  Hospitalized patients treated for catheter occlusion from January 2006 to December 2011.    MAIN MEASURES  Univariate analyses of patient characteristics and treatment patterns and multivariable regression analyses of postocclusion hospital costs, LOS, and 30‐ and 90‐day readmissions were conducted.    KEY RESULTS  We included 34,579 patients treated for a CVC occlusion by replacement (N = 1028) or by alteplase (2 mg) administration (N = 33,551). Patients receiving alteplase were somewhat younger than those having catheter replacement (60 ± 19 vs 62 ± 20 years old,  P  = 0.0002). After adjusting for patient and hospital factors via regression modeling, average daily postocclusion costs were $317 lower for alteplase recipients than for catheter replacement patients (95% confidence interval [CI]: 238.22–392.24;  P  < 0.0001). Adjusted total postocclusion costs were $1419 lower for alteplase recipients versus patients receiving catheter replacement (95% CI: 307.27–2458.12;  P  = 0.0121). Postocclusion operating room/surgery, radiology, and supply costs were significantly lower for alteplase recipients ( P  < 0.001). Average adjusted postocclusion LOS was similar for both groups ( P  > 0.05). Odds of readmission were not significantly different at 30 or 90 days.    CONCLUSIONS  Among patients treated for an occluded CVC, alteplase‐treated patients had lower daily and total postocclusion costs than patients receiving catheter replacement. Cost differences were mainly driven by lower operating room/surgery, radiology, and supplier costs.  Journal of Hospital Medicine  2014;9:490–496. © 2014 The Authors Journal of Hospital Medicine published by Wiley Periodicals, Inc. on behalf of Society of Hospital Medicine

journal of hospital medicine

Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheters